Press releases

ORYZON to Present Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia at EHA 2026

ORYZON to participate in upcoming events in May and June

ORYZON strengthens vafidemstat patent portfolio with U.S. Notice of Allowance

ORYZON announces U.S. patent grant covering iadademstat combinations with venetoclax

ORYZON expands patent protection for iadademstat with grant decision in Mexico covering combinations with PD-1/PD-L1 inhibitors

ORYZON reports financial results and corporate update for quarter ended December 31st, 2025

ORYZON receives European Medicines Agency approval to initiate a Phase II study of iadademstat in essential thrombocythemia

ORYZON to participate in upcoming events in February and March

ORYZON announces appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS

ORYZON announces first patient dosed in an Investigator-initiated Phase Ib study of iadademstat in extensive stage small cell lung cancer